Vaxcyte, Inc.

65 articles with Vaxcyte, Inc.

• Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update

  5/9/2022

  Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the first quarter ended March 31, 2022 and provided a business update.

• Vaxcyte to Participate in Upcoming Investor Conferences in May 2022

  5/3/2022

  Vaxcyte, Inc. announced that Company management will participate in and host one-on-one meetings at the following investor conferences.

• 

  Clinical Catch-Up: COVID-19, AAN, ACC

  4/11/2022

  It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.

• Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference

  4/5/2022

  Vaxcyte, Inc. today announced that Company management will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 12:45 p.m. ET.

• Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults

  4/4/2022

  Vaxcyte, Inc. announced today that the first participants were dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical study evaluating VAX-24 for the prevention of invasive pneumococcal disease (IPD) and pneumonia in adults.

• Vaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

  2/28/2022

  Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a business update.

• Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

  2/23/2022

  Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that the first participants were dosed in the Phase 1/2 clinical study of VAX-24.

• Vaxcyte to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

  2/17/2022

  Vaxcyte, Inc. (Nasdaq: PCVX), today announced that it will report financial results for the fourth quarter and full year 2021 after market close on February 28, 2022. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update.

• Vaxcyte to Present at the 11th Annual SVB Leerink Global Healthcare Conference

  2/10/2022

  Vaxcyte, Inc. today announced that Company management will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 2:20 p.m. ET / 11:20 a.m. PT.

• Vaxcyte Announces Pricing of $100 Million Public Offering

  1/13/2022

  Vaxcyte, Inc., a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced the pricing of an underwritten public offering of common stock and pre-funded warrants.

• Vaxcyte Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

  1/12/2022

  Vaxcyte, Inc. announced today that it has commenced an underwritten public offering of its common stock and pre-funded warrants.

• Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease

  1/6/2022

  Vaxcyte, Inc. (Nasdaq: PCVX), announced today that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for VAX-24, its lead, 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease.

• Vaxcyte to Present at Upcoming Investor Conferences - Nov 11, 2021

  11/11/2021

  Vaxcyte, Inc., a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, announced that Company management will participate in and host one-on-one meetings at the following virtual investor conferences.

• Vaxcyte Reports Third Quarter 2021 Financial Results and Provides Business Update

  11/10/2021

  Vaxcyte, Inc. today announced financial results for the third quarter ended September 30, 2021 and provided a business update.

• Vaxcyte Appoints Carlos Paya and Michael Kamarck to Its Board of Directors

  10/28/2021

  Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced it has appointed Carlos Paya and Michael Kamarck, accomplished industry leaders, to its board of directors.

• Vaxcyte to Present at Guggenheim 2nd Annual Vaccine and Infectious Disease Conference

  9/28/2021

  Vaxcyte, Inc. announced that Company management will participate in a fireside chat at the Guggenheim 2nd Annual Vaccine and Infectious Disease Conference on Tuesday, October 5, 2021 at 11:30am ET.

• Vaxcyte to Present at 2021 Cantor Virtual Global Healthcare Conference

  9/21/2021

  Vaxcyte, Inc. today announced that Company management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference on Tuesday, September 28, 2021 at 8:40am ET.

• Vaxcyte Appoints Annie Drapeau and Teri Loxam to Its Board of Directors

  9/20/2021

  Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced it has appointed Annie Drapeau and Teri Loxam to its board of directors.

• Vaxcyte Reports Second Quarter 2021 Financial Results and Provides Business Update

  8/11/2021

  Vaxcyte, Inc. (Nasdaq: PCVX), a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the second quarter ended June 30, 2021 and provided a business update.

• Vaxcyte Announces Expanded CARB-X Award to Advance Development of VAX-A1, a Vaccine to Prevent Group A Streptococcus Infections

  8/5/2021

  Vaxcyte, Inc. today announced an additional award of $3.2 million from CARB-X to advance development of VAX-A1, a novel vaccine designed to prevent infections caused by Group A Streptococcus pyogenes (Strep) bacteria.